These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9635244)

  • 21. Cephalosporins--cefotaxime 10 years later, a major drug with continued use.
    Neu HC
    Infection; 1991; 19 Suppl 6():S309-15. PubMed ID: 1791075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The comparative activity of cefepime and other current antibiotics against microorganisms isolated from patients in pediatric intensive therapy units].
    Kurchavov VA; Beloborodova NV; Biriukov AV; Vostrikova TIu; Rogatina EL; Krutskikh EN
    Antibiot Khimioter; 1999; 44(11):23-30. PubMed ID: 10629738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging cephalosporins.
    Page MG
    Expert Opin Emerg Drugs; 2007 Nov; 12(4):511-24. PubMed ID: 17979596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefepime: the next generation?
    Sanders CC
    Clin Infect Dis; 1993 Sep; 17(3):369-79. PubMed ID: 8218678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sensitivity to cephalosporin antibiotics of infectious causative agents in surgery].
    Bekbergenov BM; Speranskaia ON; Navashin PS
    Antibiot Khimioter; 1988 Aug; 33(8):597-601. PubMed ID: 3196117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of clinical isolates of gram-positive and gram-negative organisms to cefatrizine.
    Carlone NA; Cuffini AM; Forno Pizzoglio M; Cavallo G
    Drugs Exp Clin Res; 1985; 11(7):447-51. PubMed ID: 3836867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class.
    Deresinski SC
    Diagn Microbiol Infect Dis; 2008 May; 61(1):82-5. PubMed ID: 18384999
    [No Abstract]   [Full Text] [Related]  

  • 30. [Multiresistant bacterial strains in infections of children treated at the National Research Institute of Mother and Child in 1999].
    Drejewicz H; Toczynska B
    Med Wieku Rozwoj; 2000; 4(4):431-9. PubMed ID: 11228601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.
    Rolston KV; Bodey GP
    Infection; 1986; 14(3):139-41. PubMed ID: 3733227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
    Tariq TM
    J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Microbiological monitoring for the causative agents of nosocomial infections (exemplified by resuscitation and intensive therapy units)].
    Karabak VI
    Antibiot Khimioter; 2000; 45(3):20-3. PubMed ID: 10768062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bloodstream infections in a medical-surgical intensive care unit: incidence, aetiology, antimicrobial resistance patterns of Gram-positive and Gram-negative bacteria.
    Erdem I; Ozgultekin A; Sengoz Inan A; Ozturk Engin D; Senbayrak Akcay S; Turan G; Dincer E; Oguzoglu N; Goktas P
    Clin Microbiol Infect; 2009 Oct; 15(10):943-6. PubMed ID: 19548920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey.
    Trecarichi EM; Pagano L; Candoni A; Pastore D; Cattaneo C; Fanci R; Nosari A; Caira M; Spadea A; Busca A; Vianelli N; Tumbarello M;
    Clin Microbiol Infect; 2015 Apr; 21(4):337-43. PubMed ID: 25595706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance in intensive care units.
    Albrich WC; Angstwurm M; Bader L; Gärtner R
    Infection; 1999; 27 Suppl 2():S19-23. PubMed ID: 10885822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial organisms and antimicrobial resistance patterns.
    Varghese GK; Mukhopadhya C; Bairy I; Vandana KE; Varma M
    J Assoc Physicians India; 2010 Dec; 58 Suppl():23-4. PubMed ID: 21563609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of a "round table" on cefpirome (Keiten)].
    Navashin SM; Navashin PS
    Antibiot Khimioter; 1996; 41(12):40-2. PubMed ID: 9124985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.